Table 1.

Inclusion and exclusion criteria of the PINPOINT study

Inclusion criteria	Exclusion criteria
Provision of informed consent prior to any study-specific procedure	Treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before the study enrolment
Diagnosis of STEMI or NSTEMI	Hypersensitivity to ticagrelor
Men or non-pregnant women	Current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin
Provision of informed consent for angiography and PCI	Active bleeding
	History of intracranial haemorrhage
	Fibrinolytic treatment during the index event
	Recent gastrointestinal bleeding (within 30 days)
	History of coagulation disorders
	History of moderate or severe hepatic impairment
	History of major surgery or severe trauma (within 3 months)
	Second or third degree atrioventricular block during screening for eligibility
	Patient requiring dialysis
	Manifest infection or inflammatory state
	Killip class III or IV during screening for eligibility
	Respiratory failure
	Current therapy with strong CYP3A inhibitors or strong CYP3A inducers

NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.